Stopping treatment with immunosuppressants ‘double response to covid booster’

P.

A new study suggests that the use of immunosuppressants to treat weak people doubles their antibody response to the corona virus booster vaccine.

The researchers looked at the effect of interrupting treatment with methotrexate – which is recommended for inflammatory conditions such as rheumatoid arthritis and skin conditions such as psoriasis – up to two weeks after work.

The drug is the most widely used immune suppressant, with approximately 1.3 million people in the UK prescribing it.

The key message to take home is that interrupting treatment for two weeks after CoVID-19 B = booster vaccination doubles the immune response at week four and week 12 – a steady improvement in the immune response.

Many of them were among the 2.2 million medically weak people who, during the first stage of the CoVID-19 epidemic, depended on expert advice and their risk factors.

The researchers found that after four weeks and 12 weeks, the levels of spike antibodies in this group were more than double where the drug was stopped for two weeks after vaccination, compared to the group who continued to use.

Although there was a short-term increase in the risk of provocative outbreaks, most of them could be self-administered and did not put any pressure on the NHS, the study indicated.

Professor Abhishek Abhishek, Chief Investigator at the University of Nottingham and Honorary Consultant Rheumatologist at the Nottingham University Hospitals NHS Trust, said: And week 12 – continuous improvement in the immune response.

“However, in the four weeks after post-vaccination, when treatment is stopped for two weeks, the risk of developing the disease increases.

“It is important to keep in mind the increased risk of disease outbreaks, but most of these flames appear mild, do not require NHS assistance and are self-administered.”

The results of the study have been referred to the Joint Vaccination and Immunization Committee (JCVI), which is reviewing the findings and making recommendations.

Professor Abhishek said: “Implementing these findings could significantly improve the protection provided by Booster 19 against Covid 19 for millions of people living with these conditions.

“COVID-19 has left them with a serious illness while they still have to live with the traumatic and disturbing effects of their condition.

“We hope this evidence is the next step in helping them move on with their lives.”

Researchers have warned patients not to take matters into their own hands and to consult their doctor before making any changes to their treatment.

The study had planned to recruit 560 patients but the recruitment was halted by the independent study monitoring committees after the provisional results of the first 254 participants showed clear results.

During the trial, 127 participants were asked to suspend use of methotrexate for two weeks and 127 to continue their routine use, and spike antibody levels were compared in both groups.

The Vaccine Response on Methotrexate (VROM) trial is funded by the National Institute for Health and Care Research and the Medical Research Council.

It was led by experts from the University of Nottingham in collaboration with colleagues from the University of Manchester, Imperial College London, the University of Oxford and Queen Mary University London.

The results are published in the Lancet Respiratory Medicine.